Tharimmune (THAR) highlights Super Validator role on Canton network in 8-K

Rhea-AI Filing Summary

Tharimmune, Inc. filed a current report to highlight a corporate update. On January 26, 2026, the company issued a press release announcing its role as a Super Validator on the Canton network, signaling an operational development related to that blockchain platform. The press release is provided as Exhibit 99.1 to this report and is incorporated by reference, giving readers access to more detail on Tharimmune’s new role.

false 0001861657 0001861657 2026-01-26 2026-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 26, 2026

THARIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41210		84-2642541
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

34 Shrewsbury Avenue, Suite 1C

Red Bank, NJ 07701

(Address of principal executive offices, including zip code)

(732) 889-3111

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		THAR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 26, 2026, the Company issued a press release announcing its role as a Super Validator on the Canton network. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit
99.1		Press Release, dated January 26, 2026
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 26, 2026	Tharimmune, Inc.
	/s/ Mark Wendland
	Mark Wendland
	Chief Executive Officer

-3-

FAQ

What did Tharimmune (THAR) disclose in this 8-K filing?

Tharimmune disclosed that on January 26, 2026, it issued a press release announcing its role as a Super Validator on the Canton network. The press release is attached as Exhibit 99.1.

Which item of Form 8-K did Tharimmune (THAR) use for this disclosure?

Tharimmune used Item 8.01 – Other Events to report the press release announcing its role as a Super Validator on the Canton network.

Where can investors find more details about Tharimmune’s Super Validator role?

More details are in the press release filed as Exhibit 99.1, dated January 26, 2026, which is incorporated by reference into the report.

Does this Tharimmune (THAR) 8-K include financial statements?

Under Item 9.01, Tharimmune lists Exhibit 99.1 (the press release) and Exhibit 104 (the cover page formatted in Inline XBRL); no separate financial statements are identified in this excerpt.

Who signed the Tharimmune (THAR) 8-K report?

The report was signed on behalf of Tharimmune, Inc. by Mark Wendland, Chief Executive Officer, dated January 26, 2026.